Candel Therapeutics, Inc.
CADL
Positions held
Your positionsCADL isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $739.17M | Enterprise value | $587.12M | Trailing P/E | — | Forward P/E | -15.46 |
| PEG | — | Price / book | 5.83 | Beta | -0.31 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -81.8% | ROA | -28.6% | Debt / equity | 0.39 |
| Current ratio | 16.09 | Free cash flow | -$35.75M | Analyst recommendation | strong_buy | Mean target | $21.75 |
| 52w high | $14.00 | 52w low | $4.35 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$38.9M | -$8.9M | -$29.5M | -$11.3M | -$4.8M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$26.7M | -$16.3M | -$15.7M | -$13.2M | -$11.2M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.1M | — |
| Op margin | — | — | — | -27739.2% | — |
| Net income | -$38.2M | -$55.2M | -$37.9M | -$18.8M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$48.2M | -$33.4M | -$38.4M | -$34.7M | — |
Headlines — positive tone
• [OK · fundamentals] Candel Therapeutics Shares Rise After BofA Upgrade
News
2026-10-02 · Candel Therapeutics to Present at the SITC 2026 Annual Meeting
2026-10-01 · Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-30 · CADL Slips Despite Encouraging Prostate Cancer Drug Data — Retail Believes Stock Is ‘Clearly A Buy And Hold’
2026-09-21 · Candel Therapeutics Shares Rise After BofA Upgrade
2026-09-21 · BofA Upgrades Candel Therapeutics to Buy From Neutral, Price Target is $18
2026-09-16 · The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux
2026-09-15 · 4 Prostate Cancer Drug Stocks to Watch During Awareness Month
2026-09-14 · Candel Therapeutics Insider Sold Shares Worth $3,160,783, According to a Recent SEC Filing
2026-09-10 · Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors
Price (daily)
Full chart · RSI · MACD · patterns